← back to search

Byung‐Wan Lee

Yonsei University · KR
Area of research
Endocrinology, Diabetes and Metabolism · Epidemiology
Research interest
Research interests include Diabetes Treatment and Management, Liver Disease Diagnosis and Treatment, Diabetes, Cardiovascular Risks, and Lipoproteins, and Diabetes Management and Research.
h-index
52
citations
18,156
works
406
NIH funding
primary concept
Medicine
email

Recent publications

Hyperoxia-induced fatty liver injury through the AKT-dependent and HIF-2α-independent pathways.
2026cited by 0position: contributordoi
Standardizing the Accuracy and Performance Evaluation Metrics of Integrated Continuous Glucose Monitors in the Asia-Pacific Region.
2026cited by 0position: contributordoi
Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial.
2026cited by 0position: contributordoi
Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real-World Observational Study.
2026cited by 0position: contributordoi
Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial.
2026cited by 0position: contributordoi
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
Nephrology Dialysis Transplantation 2025cited by 18position: middledoi
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.
2025cited by 15position: contributordoi
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.
2025cited by 8position: contributordoi
Ketone Body Induction: Insights into Metabolic Disease Management.
2025cited by 7position: contributordoi
Association between serum beta-hydroxybutyrate levels and risk of type 2 diabetes mellitus in patients with impaired fasting glucose.
2025cited by 3position: contributordoi
Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
2025cited by 3position: contributordoi
Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
2025cited by 2position: contributordoi
Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes.
2025cited by 1position: contributordoi
Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial.
2025cited by 1position: contributordoi
Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.
2025cited by 1position: contributordoi
Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease.
2025cited by 1position: contributordoi
Meeting Physical Activity Guidelines: Impact on Chronic Kidney Disease Prevalence in Diabetic Individuals.
2025cited by 1position: contributordoi
Safety and effectiveness of pregabalin controlled-release in Korean patients with peripheral neuropathic pain: A post-marketing surveillance data.
2025cited by 0position: contributordoi
DA-9701 (Motilitone®) improves glucose homeostasis by protecting STZ-induced β-cells death.
2025cited by 0position: contributordoi
Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022.
2025cited by 0position: contributordoi
Protective Role of Serum β-Hydroxybutyrate in Early Diabetic Kidney Disease: A Longitudinal Study.
2025cited by 0position: contributordoi
The Impact of Ketogenic Capacity on Lipid Profile in Individuals with Prediabetes or Newly Diagnosed Type 2 Diabetes.
2025cited by 0position: contributordoi
Potential Impact of Choline Alphoscerate on Depressive Symptoms in Association with Insulin Resistance in Elderly Patients with Type 2 Diabetes.
2025cited by 0position: contributordoi
Impact of Type 2 Diabetes Mellitus on Age at Death in the Hemodialysis Population: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
Diabetology 2025cited by 0position: contributordoi
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.
2024cited by 44position: contributordoi
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
2024cited by 33position: contributordoi
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
2024cited by 29position: contributordoi
Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study.
2024cited by 9position: contributordoi
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
2024cited by 7position: contributordoi
Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities.
2024cited by 7position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Yong‐ho Lee · Yonsei University61 papers (2019–2026) · 55 papers (2019–2026) · 27 papers (2019–2026)Eugene Han · Keimyung University14 papers (2019–2025)Eun Seok Kang · Yonsei University11 papers (2019–2026)Bong-Soo Cha · Yonsei University11 papers (2019–2026) · 10 papers (2019–2026)Jaehyun Bae · Hallym University Kangnam Sacred Heart Hospital9 papers (2020–2026)Seung Up Kim · University of Cincinnati9 papers (2020–2024)Gyuri Kim · Myongji University7 papers (2019–2021)Sang Hoon Ahn · Eisai (Japan)6 papers (2020–2024)Sun Ok Song · National Health Insurance Service Ilsan Hospital5 papers (2020–2025)Sin Gon Kim · Seoul National University4 papers (2019–2026)Beom Kyung Kim · Eisai (Japan)4 papers (2020–2023)Yongin Cho · Inha University4 papers (2019–2020)Woo Je Lee · Ulsan College3 papers (2019–2025)Hye Won Lee · Yonsei University3 papers (2022–2023)Hye Soon Kim · Keimyung University Dongsan Medical Center3 papers (2019–2022)Justin Y. Jeon · The University of Texas at Austin3 papers (2020–2025)Sun Ha Jee · Ajou University3 papers (2022–2025)